Enrique
Bernal Morell
Profesor Contratado Doctor Tipo a (Vinculado)
Hospital Universitario La Paz
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario La Paz (23)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701
-
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
BMC Infectious Diseases, Vol. 23, Núm. 1
2022
-
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Open Forum Infectious Diseases
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Integrase inhibitors in children and adolescents: Clinical use and resistance
Journal of Antimicrobial Chemotherapy, Vol. 77, Núm. 10, pp. 2784-2792
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
The Lancet HIV, Vol. 8, Núm. 4, pp. e185-e196
-
Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort
Pulmonology, Vol. 27, Núm. 5, pp. 403-412
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2019
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
-
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
International Journal of Infectious Diseases, Vol. 83, pp. 72-76
-
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report
European Respiratory Journal, Vol. 54, Núm. 6
2018
-
Dalbavancin in the treatment of different gram-positive infections: a real-life experience
International Journal of Antimicrobial Agents, Vol. 51, Núm. 4, pp. 571-577
-
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Open Forum Infectious Diseases, Vol. 5, Núm. 1
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596